Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anktiva in Long Covid
NCT07108036Phase 2Recruiting
- Sponsor
- ImmunityBio, Inc.
- Start
- Nov 2025
- Primary completion
- Oct 2026
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nogapendekin alfa inbakicept in post-COVID-19 condition (PCC), sponsored by ImmunityBio, Inc. Primary endpoints: Incidence of treatment emergent adverse events at 30 days, Incidence of grade 3 or higher TEAEs at 30 days and 3 more. Started Nov 2025; status: recruiting.
02
Drugs
nogapendekin alfa inbakicept
03
Conditions
post-COVID-19 condition (PCC)
Beyond the preview
Go deeper on NCT07108036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07108036.